Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Legal Names
Legal name
Similar Companies1000
EndoCyclic Therapeutics
EndoCyclic Therapeutics develops non-hormonal therapies for endometriosis.
Sector
Subsector
Keywords
Location
Opera Therapeutics
Opera Therapeutics is developing biologic treatments for diabetic retinopathy and stroke-induced edema.
Sector
Subsector
Keywords
Location
total rounds
MUVON Therapeutics
Muvon Therapeutics develops autologous cell therapies to restore skeletal muscle.
Sector
Subsector
Keywords
Location
total rounds
total raised
Tafalgie Therapeutics
Tafalgie Therapeutics develops next-gen pain treatments using innovative protein-based technology.
Sector
Subsector
Location
total rounds
M&A Details1
Financials
Funding Rounds1
Number of Funding Rounds
Money Raised
Their latest funding was raised on 29.08.2018. Their latest investor OrbiMed. Their latest round Series C
Fountain Healthcare Partners
Fountain Healthcare Partners is an Irish-based life science venture capital fund.
Sector
Subsector
Location
count Of Investments
count Of Exists
Longitude Capital
Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors5
Number of lead investors
Number of investors
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Forbion
Netherlands-based venture capital firm investing in life sciences and MedTech companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Advent Life Sciences
Advent Life Sciences is a leading European venture team investing in life sciences businesses.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders2
Mike Trower
Mike is Co-founder and Chief Scientific Officer of KaNDy Therapeutics. It was Mike’s advocacy of the dual mechanism neurokinin-1,3 receptor antagonism, offered by NT-814, to present a novel and potentially transformational non-hormonal therapy for treatment of symptoms of the menopause and other related Women’s Health conditions which led to NT-814 being spun out of NeRRe Therapeutics to create KaNDy Therapeutics in 2017. Mike has broad knowledge of neurokinin receptor biology and, in particular, the emerging science that has established the pivotal role these systems play in neuroendocrinology and female sex-hormone related disorders. Mike is also Co-founder and CSO of NeRRe Therapeutics whose focus is on developing the neurokinin-1 receptor antagonist orvepitant to treat neuronal hypersensitivity disorders including chronic refractory cough. Prior to founding NeRRe, Mike worked in pharmaceutical industry R&D at GSK for nearly 20 years, where latterly he was VP & Head of the External Drug Discovery Group in the Neurosciences Centre for Excellence for Drug Discovery (CEDD). In this position, Mike successfully implemented the CEDD externalisation strategy and advanced a portfolio of preclinical and clinical pipeline assets. Mike has BSc (Hons) and PhD degrees in biological sciences and has held post-doctoral positions at DuPont Inc in Delaware, US, and at the Medical Research Council in Cambridge, UK, under the Nobel laureate Professor Sydney Brenner.
current job
organization founded
Mike Trower
Mary Kerr
Mary co-founded KaNDy Therapeutics in 2017 as a spin out from NeRRe Therapeutics. KaNDy was formed to ensure a single-minded focus in developing NT-814 as a novel and breakthrough treatment for symptoms of the menopause. Mary has held a range of senior leadership roles in the pharmaceutical industry having spent the majority of her career on the R&D/commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. She was a founding member of the executive team of ViiV Healthcare (the independent, HIV company that combines the HIV expertise of GSK, Pfizer Inc. and Shionogi) where she led, revitalised and grew the business throughout Europe. Mary was also previously Senior Vice President and Global Franchise Head at GSK. Mary also currently serves as CEO of NeRRe and is a non-executive independent director at Galapagos NV. Mary gained a PhD in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation, Detroit and has an MBA from the University of Kingston.
current job
organization founded
Mary Kerr
Employee Profiles2
Mike Trower
Co-Founder and Chief Scientific Officer